5 Stocks Pulling The Drugs Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 58 points (-0.4%) at 15,461 as of Wednesday, Aug. 7, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 785 issues advancing vs. 2,161 declining with 94 unchanged.

The Drugs industry currently sits down 0.6% versus the S&P 500, which is down 0.4%. A company within the industry that fell today was Biogen Idec ( BIIB), up 0.8%. Top gainers within the industry include Santarus ( SNTS), up 8.5%, Biomarin Pharmaceutical ( BMRN), up 2.1%, Celgene Corporation ( CELG), up 1.4%, Amgen ( AMGN), up 1.8% and Sanofi ( SNY), up 0.8%.

TheStreet would like to highlight 5 stocks pushing the industry lower today:

5. Inovio Pharmaceuticals ( INO) is one of the companies pushing the Drugs industry lower today. As of noon trading, Inovio Pharmaceuticals is down $0.66 (-25.4%) to $1.94 on heavy volume. Thus far, 22.0 million shares of Inovio Pharmaceuticals exchanged hands as compared to its average daily volume of 5.2 million shares. The stock has ranged in price between $1.77-$2.29 after having opened the day at $2.29 as compared to the previous trading day's close of $2.60.

Inovio Pharmaceuticals, Inc., together with its subsidiaries, engages in the discovery and development of synthetic vaccines and immune therapies focusing on cancers and infectious diseases. Inovio Pharmaceuticals has a market cap of $539.8 million and is part of the health care sector. Shares are up 500.6% year to date as of the close of trading on Tuesday. Currently there are 5 analysts that rate Inovio Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Inovio Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income and feeble growth in its earnings per share. Get the full Inovio Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Investors Need to Closely Watch Mario Draghi's Speech at Jackson Hole: Market Recon

Resist All the Dow 22K Hoopla: Cramer's 'Mad Money' Recap (Wednesday 8/2/17)

Chevron, Universal Display, Dynavax Technologies, Schlumberger: 'Mad Money' Lightning Round

These Stocks Are Ready to Reverse Course

Biotech Movers: Sarepta, Inovio, Mylan